J. Hambleton

1.5k total citations
18 papers, 1.1k citations indexed

About

J. Hambleton is a scholar working on Oncology, Molecular Biology and Internal Medicine. According to data from OpenAlex, J. Hambleton has authored 18 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Internal Medicine. Recurrent topics in J. Hambleton's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (6 papers) and Venous Thromboembolism Diagnosis and Management (3 papers). J. Hambleton is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (6 papers) and Venous Thromboembolism Diagnosis and Management (3 papers). J. Hambleton collaborates with scholars based in United States, Canada and Switzerland. J. Hambleton's co-authors include Anthony DeFranco, Stuart L. Weinstein, Lawrence Lem, Martin McMahon, Herbert I. Hurwitz, Fairooz F. Kabbinavar, Eric Holmgren, William Novotny, Matthew S. Brown and Marc Rodger and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

J. Hambleton

18 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Hambleton United States 15 352 343 273 218 173 18 1.1k
Masaru Ido Japan 18 277 0.8× 245 0.7× 200 0.7× 114 0.5× 34 0.2× 80 1.1k
Susanne Pfeiler Germany 17 444 1.3× 813 2.4× 107 0.4× 125 0.6× 187 1.1× 27 1.6k
Lemin Wang China 17 434 1.2× 161 0.5× 120 0.4× 160 0.7× 85 0.5× 80 1.0k
Dorothée Faille France 15 264 0.8× 293 0.9× 78 0.3× 72 0.3× 117 0.7× 39 1.1k
Sherry L. Spinelli United States 25 725 2.1× 232 0.7× 150 0.5× 94 0.4× 44 0.3× 49 1.9k
Wenjuan Yang China 23 655 1.9× 227 0.7× 326 1.2× 310 1.4× 23 0.1× 102 1.5k
D. Maroeska W. M. te Loo Netherlands 22 297 0.8× 310 0.9× 219 0.8× 93 0.4× 18 0.1× 73 1.5k
Takayuki Iwaki Japan 18 202 0.6× 183 0.5× 51 0.2× 105 0.5× 66 0.4× 44 1.1k
Xueping Wang China 23 353 1.0× 210 0.6× 428 1.6× 267 1.2× 22 0.1× 83 1.3k
Hans Peter Schwarz Austria 22 306 0.9× 422 1.2× 97 0.4× 84 0.4× 167 1.0× 60 1.9k

Countries citing papers authored by J. Hambleton

Since Specialization
Citations

This map shows the geographic impact of J. Hambleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Hambleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Hambleton more than expected).

Fields of papers citing papers by J. Hambleton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Hambleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Hambleton. The network helps show where J. Hambleton may publish in the future.

Co-authorship network of co-authors of J. Hambleton

This figure shows the co-authorship network connecting the top 25 collaborators of J. Hambleton. A scholar is included among the top collaborators of J. Hambleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Hambleton. J. Hambleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Leighl, Natasha B., Jaafar Bennouna, Yi Jiang, et al.. (2011). Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. British Journal of Cancer. 104(3). 413–418. 43 indexed citations
2.
Pope, Whitney B., Qingsong Xia, Virginia Paton, et al.. (2011). Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 76(5). 432–437. 93 indexed citations
3.
Cannistra, S A, U. Matulonis, Richard T. Penson, et al.. (2006). Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Journal of Clinical Oncology. 24(18_suppl). 5006–5006. 43 indexed citations
4.
Kahn, Susan R., Clive Kearon, J.A. Julian, et al.. (2005). Predictors of the post‐thrombotic syndrome during long‐term treatment of proximal deep vein thrombosis. Journal of Thrombosis and Haemostasis. 3(4). 718–723. 147 indexed citations
5.
Kozloff, M., Allen Lee Cohn, Patrick J. Flynn, et al.. (2005). Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S. Journal of Clinical Oncology. 23(16_suppl). 3566–3566. 17 indexed citations
6.
Hambleton, J., Jamey Skillings, Fairooz F. Kabbinavar, et al.. (2005). Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 23(16_suppl). 3554–3554. 35 indexed citations
7.
Hambleton, J., William Novotny, Herbert I. Hurwitz, et al.. (2004). Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Journal of Clinical Oncology. 22(14_suppl). 3528–3528. 45 indexed citations
8.
Mass, R., G. Fyfe, J. Hambleton, et al.. (2004). Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis. Journal of Clinical Oncology. 22(14_suppl). 3616–3616. 18 indexed citations
9.
Hambleton, J., William Novotny, Herbert I. Hurwitz, et al.. (2004). Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Journal of Clinical Oncology. 22(14_suppl). 3528–3528. 23 indexed citations
10.
Mass, R., G. Fyfe, J. Hambleton, et al.. (2004). Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis. Journal of Clinical Oncology. 22(14_suppl). 3616–3616. 5 indexed citations
11.
Burlingame, Janet, et al.. (2001). Maternal and fetal outcomes in pregnancies affected by von Willebrand disease type 2. American Journal of Obstetrics and Gynecology. 184(2). 229–230. 17 indexed citations
12.
Finn, Alexander J., et al.. (1998). The role of tyrosine kinases and map kinases in LPS-induced signaling.. PubMed. 397. 119–36. 47 indexed citations
13.
Hambleton, J.. (1996). Hematologic complications of HIV infection.. PubMed. 10(5). 671–80. 43 indexed citations
14.
Hambleton, J., Stuart L. Weinstein, Lawrence Lem, & Anthony DeFranco. (1996). Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages.. Proceedings of the National Academy of Sciences. 93(7). 2774–2778. 417 indexed citations
15.
Hambleton, J., Tomás Aragón, Gunnard Modin, Donald W. Northfelt, & Michiel A. J. van de Sande. (1995). Outcome for Hospitalized Patients with Fever and Neutropenia Who Are Infected with the Human Immunodeficiency Virus. Clinical Infectious Diseases. 20(2). 363–371. 8 indexed citations
16.
Hambleton, J., Martin McMahon, & Anthony DeFranco. (1995). Activation of Raf-1 and mitogen-activated protein kinase in murine macrophages partially mimics lipopolysaccharide-induced signaling events.. The Journal of Experimental Medicine. 182(1). 147–154. 105 indexed citations
17.
DeFranco, A L, J. Hambleton, Martin McMahon, & Stuart L. Weinstein. (1995). Examination of the role of MAP kinase in the response of macrophages to lipopolysaccharide.. PubMed. 392. 407–20. 30 indexed citations
18.
Patton, Lauren L., et al.. (1985). Childbirth preparation and outcomes of labor and delivery in primiparous women.. PubMed. 20(4). 375–8. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masaru Ido Breakdown of academic impact, for papers by Susanne Pfeiler Breakdown of academic impact, for papers by Lemin Wang Breakdown of academic impact, for papers by Dorothée Faille Breakdown of academic impact, for papers by Sherry L. Spinelli Breakdown of academic impact, for papers by Wenjuan Yang Breakdown of academic impact, for papers by D. Maroeska W. M. te Loo Breakdown of academic impact, for papers by Takayuki Iwaki Breakdown of academic impact, for papers by Xueping Wang Breakdown of academic impact, for papers by Hans Peter Schwarz
Rankless by CCL
2026